OVAL: A Potential Drug Target and Biomarker (G148756)

Target Name: OVAAL

NCBI ID: G148756

OVAAL

Other Name(s): OVAL | ovarian adenocarcinoma amplified long non-coding RNA | Ovarian adenocarcinoma amplified long non-coding RNA | RMEL2 | LINC01131

OVAL: A Potential Drug Target and Biomarker

OVAL (Ovary-derived adenosine) is a molecule that is derived from the ovaries and has been shown to have various biological effects. One of the most promising aspects of OVAL is its potential as a drug target or biomarker. This is because of its unique structure and the effects it has been shown to have on various cellular processes.

OVAL is a small molecule that is derived from the ovaries. It is a synthetic compound that is derived from the ovary, and it has been shown to have various biological effects. One of the most promising aspects of OVAL is its potential as a drug target or biomarker.

OVAL has a unique structure that is derived from the ovary. It has a long, linear carbon chain and a single oxygen atom at the end. This structure allows it to have a wide range of potential applications in medicine.

OVAL has been shown to have various biological effects on various cellular processes. One of the most interesting effects of OVAL is its ability to regulate the production of reactive oxygen species (ROS). ROS are free radicals that can cause damage to cells and contribute to various diseases, including cancer, neurodegenerative diseases, and aging.

OVAL has been shown to have a unique ability to inhibit the production of ROS. This has potential implications for the treatment of various diseases. For example, OVAL has been shown to have the potential to be a treatment for cancer, as it has been shown to inhibit the production of ROS, which can contribute to the development and progression of cancer.

OVAL has also been shown to have potential as a biomarker for certain diseases. For example, OVAL has been shown to have a unique ability to diagnose and monitor certain types of cancer, as it has been shown to bind to certain proteins that are expressed in the cells of people with certain types of cancer. This has potential implications for the development of more targeted and effective treatments for cancer.

OVAL is also a good candidate as a drug target. Its unique structure and the various biological effects it has been shown to have make it an attractive target for the development of new drugs. For example, OVAL has been shown to have the potential to be a treatment for various neurological disorders, as it has been shown to regulate the production of ROS, which can contribute to the development and progression of these disorders.

In conclusion, OVAL is a small molecule that is derived from the ovaries and has been shown to have various biological effects. Its unique structure and the effects it has been shown to have make it an attractive target for the development of new drugs and biomarkers. Further research is needed to fully understand the potential implications of OVAL and its potential as a drug target and biomarker.

Protein Name: Ovarian Adenocarcinoma Amplified Long Non-coding RNA

The "OVAAL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OVAAL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets